Yale University School of Medicine, USA “Development of anticancer treatment that penetrates cancer defense network and attacks cancer cells”
Stealth bombers are American strategic bombers that attack targets in enemy territory without being detected by enemy radar. Like stealth bombers, cancer treatment that can penetrate cancer defenses and kill cancer cells such as brain tumors has been developed.
A research team at Yale University School of Medicine in the United States announced that they have developed a new cancer treatment that cleverly evades the cancer’s defense system and attacks cancer cells by secretly hiding tumor-fighting antibodies in the molecules that cancer uses to promote tumor growth. The research team named this cancer treatment ‘Antinuclear Missile Cancer Therapy’. It is also known as ‘Trojan Horse Therapy’.
The results of this study (Cathepsin B Nuclear Flux in a DNA-Guided “Antinuclear Missile” Cancer Therapy) were published in ACS Central Science, a journal published by the American Chemical Society (ACS), and introduced by the American health and medical media outlet MedicalXpress.
According to the research team, this new anticancer treatment was shown to be effective in treating various types of cancer, including brain tumors that are difficult to treat, due to the ‘protective blood-brain barrier’, according to the results of experiments on mice.
“This new approach to cancer therapy is possible thanks to the ‘carrier antibody (antinuclear antibody)’ that has been redesigned in lupus to take advantage of its ability to target and attack tumors,” said study lead author Dr. James Hansen, a radiation oncologist at Yale Cancer Center. The antinuclear antibody secretly rides on a ‘nucleic acid molecule’ and, once inside the tumor, it removes its disguise and launches an antinuclear missile to kill the cancer cell. The nucleic acid molecule creates new DNA (deoxyribonucleic acid) and helps the tumor grow.
This chemotherapy is different from other chemotherapy treatments that combine conventional antibodies with chemotherapy. The antibodies in this chemotherapy are circulating and do not seek out and attack specific tumor cell surface markers (such as HER2, PD-L1, etc.). Instead, they infiltrate the tumor environment unnoticed. This targeted therapy greatly reduces toxic side effects.
“Antinuclear antibody-drug conjugates (ANADC) detect DNA exudates floating around tumors and track them, even when the tumors don’t have specific surface receptors and aren’t visible to other antibodies,” said Dr. Hansen. “Antinuclear antibody-drug conjugates have shown to improve survival in mice with brain tumors (gliomas) and have also shown promise in breast cancer and colon cancer.” The research team is working to advance this anticancer therapy to a clinical trial setting.
According to the research team, the antinuclear antibody-antibody conjugate targets extracellular nucleic acids instead of surface receptors. This makes it possible to target all tumors regardless of cancer type. It is likely to be applied to other diseases as well. Using antinuclear antibodies, drugs, proteins, gene therapy, etc. can be delivered to sites of damage associated with increased DNA release, such as tumors, heart attacks, strokes, and trauma.
Source: kormedi.com
